{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:24:16Z","timestamp":1793316256860,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02612-9","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T07:41:21Z","timestamp":1773906081000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["SHR-A1811, a novel HER2-targeting antibody-drug conjugate, in advanced solid tumors (HORIZON-X): a global phase 1 trial"],"prefix":"10.1038","volume":"11","author":[{"given":"Herui","family":"Yao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongsheng","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinhong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongmei","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Hee","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shusuan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jee Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shouman","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahua","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Voskoboynik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Kaubisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2083-235X","authenticated-orcid":false,"given":"Caigang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seock-Ah","family":"Im","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3153-7786","authenticated-orcid":false,"given":"Lingying","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingbin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"Ganju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minal","family":"Barve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3406-7612","authenticated-orcid":false,"given":"Guangyu","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mudan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lequn","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianli","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaijing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shangyi","family":"Rong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erwei","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,19]]},"reference":[{"key":"2612_CR1","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.phrs.2013.11.002","volume":"79","author":"R Roskoski Jr.","year":"2014","unstructured":"Roskoski, R. Jr. The ErbB\/HER family of protein-tyrosine kinases and cancer. Pharm. Res. 79, 34\u201374 (2014).","journal-title":"Pharm. Res."},{"key":"2612_CR2","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41571-019-0268-3","volume":"17","author":"DY Oh","year":"2020","unstructured":"Oh, D. Y. & Bang, Y. J. HER2-targeted therapies - a role beyond breast cancer. Nat. Rev. Clin. Oncol. 17, 33\u201348 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2612_CR3","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/modpathol.2011.198","volume":"25","author":"J R\u00fcschoff","year":"2012","unstructured":"R\u00fcschoff, J. et al. HER2 testing in gastric cancer: a practical approach. Mod. Pathol. 25, 637\u2013650 (2012).","journal-title":"Mod. Pathol."},{"key":"2612_CR4","first-page":"122","volume":"2","author":"AC Garrido-Castro","year":"2013","unstructured":"Garrido-Castro, A. C. & Felip, E. HER2 driven non-small cell lung cancer (NSCLC): potential therapeutic approaches. Transl. Lung Cancer Res. 2, 122\u2013127 (2013).","journal-title":"Transl. Lung Cancer Res."},{"key":"2612_CR5","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1056\/NEJMoa052306","volume":"353","author":"MJ Piccart-Gebhart","year":"2005","unstructured":"Piccart-Gebhart, M. J. et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353, 1659\u20131672 (2005).","journal-title":"N. Engl. J. Med."},{"key":"2612_CR6","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1056\/NEJMoa1413513","volume":"372","author":"SM Swain","year":"2015","unstructured":"Swain, S. M. et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N. Engl. J. Med. 372, 724\u2013734 (2015).","journal-title":"N. Engl. J. Med."},{"key":"2612_CR7","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1016\/S1470-2045(18)30481-9","volume":"19","author":"J Tabernero","year":"2018","unstructured":"Tabernero, J. et al. Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study. Lancet Oncol. 19, 1372\u20131384 (2018).","journal-title":"Lancet Oncol."},{"key":"2612_CR8","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1200\/JCO.20.01894","volume":"39","author":"SRD Johnston","year":"2021","unstructured":"Johnston, S. R. D. et al. Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Updated Results of ALTERNATIVE. J. Clin. Oncol. 39, 79\u201389 (2021).","journal-title":"J. Clin. Oncol."},{"key":"2612_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-022-02708-3","volume":"20","author":"J Wu","year":"2022","unstructured":"Wu, J. et al. Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial. BMC Med. 20, 498 (2022).","journal-title":"BMC Med"},{"key":"2612_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-076065","volume":"383","author":"F Ma","year":"2023","unstructured":"Ma, F. et al. Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial. BMJ 383, e076065 (2023).","journal-title":"BMJ"},{"key":"2612_CR11","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1634\/theoncologist.2008-0816","volume":"13","author":"Q Ryan","year":"2008","unstructured":"Ryan, Q. et al. FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2. Oncologist 13, 1114\u20131119 (2008).","journal-title":"Oncologist"},{"key":"2612_CR12","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","volume":"386","author":"J Cort\u00e9s","year":"2022","unstructured":"Cort\u00e9s, J. et al. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. N. Engl. J. Med. 386, 1143\u20131154 (2022).","journal-title":"N. Engl. J. Med."},{"key":"2612_CR13","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1016\/j.annonc.2020.06.020","volume":"31","author":"F Montemurro","year":"2020","unstructured":"Montemurro, F. et al. Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial. Ann. Oncol. 31, 1350\u20131358 (2020).","journal-title":"Ann. Oncol."},{"key":"2612_CR14","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","volume":"382","author":"K Shitara","year":"2020","unstructured":"Shitara, K. et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. N. Engl. J. Med. 382, 2419\u20132430 (2020).","journal-title":"N. Engl. J. Med."},{"key":"2612_CR15","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41392-024-02108-4","volume":"10","author":"X Xiong","year":"2025","unstructured":"Xiong, X. et al. Breast cancer: pathogenesis and treatments. Signal Transduct. Target Ther. 10, 49 (2025).","journal-title":"Signal Transduct. Target Ther."},{"key":"2612_CR16","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nrd.2016.268","volume":"16","author":"A Beck","year":"2017","unstructured":"Beck, A., Goetsch, L., Dumontet, C. & Corva\u00efa, N. Strategies and challenges for the next generation of antibody\u2012drug conjugates. Nat. Rev. Drug Discov. 16, 315\u2013337 (2017).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2612_CR17","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0140-6736(22)02420-5","volume":"401","author":"SA Hurvitz","year":"2023","unstructured":"Hurvitz, S. A. et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet 401, 105\u2013117 (2023).","journal-title":"Lancet"},{"key":"2612_CR18","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi, S. et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N. Engl. J. Med. 387, 9\u201320 (2022).","journal-title":"N. Engl. J. Med."},{"key":"2612_CR19","doi-asserted-by":"publisher","first-page":"4852","DOI":"10.1200\/JCO.23.01361","volume":"41","author":"K Goto","year":"2023","unstructured":"Goto, K. et al. Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial. J. Clin. Oncol. 41, 4852\u20134863 (2023).","journal-title":"J. Clin. Oncol."},{"key":"2612_CR20","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/S1470-2045(23)00215-2","volume":"24","author":"E Van Cutsem","year":"2023","unstructured":"Van Cutsem, E. et al. Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study. Lancet Oncol. 24, 744\u2013756 (2023).","journal-title":"Lancet Oncol."},{"key":"2612_CR21","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1200\/JCO.23.02005","volume":"42","author":"F Meric-Bernstam","year":"2024","unstructured":"Meric-Bernstam, F. et al. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial. J. Clin. Oncol. 42, 47\u201358 (2024).","journal-title":"J. Clin. Oncol."},{"key":"2612_CR22","doi-asserted-by":"crossref","unstructured":"Powell, C. A. et al. Pooled analysis of drug-related interstitial lung disease and\/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies. ESMO Open 7, 100554 (2022).","DOI":"10.1016\/j.esmoop.2022.100554"},{"key":"2612_CR23","doi-asserted-by":"crossref","unstructured":"Guidi, L., Pellizzari, G., Tarantino, P., Valenza, C. & Curigliano, G. Resistance to Antibody\u2012Drug Conjugates Targeting HER2 in Breast Cancer: Molecular Landscape and Future Challenges. Cancers (Basel) 15, 1130 (2023).","DOI":"10.3390\/cancers15041130"},{"key":"2612_CR24","doi-asserted-by":"publisher","first-page":"e0326691","DOI":"10.1371\/journal.pone.0326691","volume":"20","author":"T Zhang","year":"2025","unstructured":"Zhang, T. et al. SHR-A1811, a novel anti-HER2 antibody\u2012drug conjugate with optimal drug-to-antibody ratio, efficient tumor killing potency, and favorable safety profiles. PLoS One 20, e0326691 (2025).","journal-title":"PLoS One"},{"key":"2612_CR25","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.annonc.2025.02.011","volume":"36","author":"JJ Li","year":"2025","unstructured":"Li, J. J. et al. Efficacy and safety of neoadjuvant SHR-A1811 with or without pyrotinib in women with locally advanced or early HER2-positive breast cancer: a randomized, open-label, phase II trial. Ann. Oncol. 36, 651\u2013659 (2025).","journal-title":"Ann. Oncol."},{"key":"2612_CR26","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/s41392-024-01897-y","volume":"9","author":"Z Li","year":"2024","unstructured":"Li, Z. et al. SHR-A1811 (antibody\u2012drug conjugate) in advanced HER2-mutant non-small cell lung cancer: a multicenter, open-label, phase 1\/2 study. Signal Transduct. Target Ther. 9, 182 (2024).","journal-title":"Signal Transduct. Target Ther."},{"key":"2612_CR27","doi-asserted-by":"publisher","first-page":"3453","DOI":"10.1200\/JCO.23.02044","volume":"42","author":"H Yao","year":"2024","unstructured":"Yao, H. et al. Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2-Directed Antibody\u2012Drug Conjugate, in Human Epidermal Growth Factor Receptor 2-Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial. J. Clin. Oncol. 42, 3453\u20133465 (2024).","journal-title":"J. Clin. Oncol."},{"key":"2612_CR28","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1914510","volume":"382","author":"S Modi","year":"2020","unstructured":"Modi, S. et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. N. Engl. J. Med. 382, 610\u2013621 (2020).","journal-title":"N. Engl. J. Med."},{"key":"2612_CR29","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1056\/NEJMoa2112431","volume":"386","author":"BT Li","year":"2022","unstructured":"Li, B. T. et al. Trastuzumab Deruxtecan in HER2-Mutant; Small-Cell Lung Cancer. N. Engl. J. Med. 386, 241\u2013251 (2022).","journal-title":"N. Engl. J. Med."},{"key":"2612_CR30","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.ccell.2022.09.016","volume":"40","author":"R Colombo","year":"2022","unstructured":"Colombo, R. & Rich, J. R. The therapeutic window of antibody drug conjugates: A dogma in need of revision. Cancer Cell 40, 1255\u20131263 (2022).","journal-title":"Cancer Cell"},{"key":"2612_CR31","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/S0140-6736(23)00725-0","volume":"401","author":"F Andr\u00e9","year":"2023","unstructured":"Andr\u00e9, F. et al. Trastuzumab deruxtecan versus treatment of physician\u2019s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial. Lancet 401, 1773\u20131785 (2023).","journal-title":"Lancet"},{"key":"2612_CR32","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1158\/0008-5472.CAN-24-2021","volume":"85","author":"Q Wei","year":"2025","unstructured":"Wei, Q. et al. Perivascular Niche-Resident Alveolar Macrophages Promote Interstitial Pneumonitis Related to Trastuzumab Deruxtecan Treatment. Cancer Res. 85, 2081\u20132099 (2025).","journal-title":"Cancer Res."},{"key":"2612_CR33","doi-asserted-by":"publisher","first-page":"e13006","DOI":"10.1200\/JCO.2024.42.16_suppl.e13006","volume":"42","author":"M Yan","year":"2024","unstructured":"Yan, M. et al. Efficacy and safety of HER2-ADC SHR-A1811 in HER2-positive breast cancer with brain metastases. J. Clin. Oncol. 42, e13006\u2013e13006 (2024).","journal-title":"J. Clin. Oncol."},{"key":"2612_CR34","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","volume":"391","author":"A Bardia","year":"2024","unstructured":"Bardia, A. et al. Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer. N. Engl. J. Med. 391, 2110\u20132122 (2024).","journal-title":"N. Engl. J. Med."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02612-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02612-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02612-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T07:41:25Z","timestamp":1773906085000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02612-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,19]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2612"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02612-9","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,19]]},"assertion":[{"value":"5 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Kaijing Zhao, Yu Shen, Shangyi Rong, and Xiaoyu Zhu reported being employed by Jiangsu Hengrui Pharmaceuticals Co., Ltd. No other disclosures were reported.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"104"}}